0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV228.95%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma30.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Regulus Therapeutics Stock Discussion
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vanguard loaded
Regulus Therapeutics Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol RGLS, has recently announced positive topline results from the third cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) clinical trial of RGLS8429. This investigational drug is being developed for the treatment of ...
No comment yet